Movement Disorders

The findings suggest that patients with dementia should be prioritized for stringent preventive measures, greater surveillance, and early intervention in COVID-19.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 21, 2021.

A budget impact analysis suggested that Cala Health’s Cala Trio device can serve as a cost-saving treatment option for patients with ET.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed future ideas for the MANAGE-PD tool to furthering its benefits.

The assistant professor of neurology at the Keck School of Medicine at University of Southern California shared her insight into the study data and the therapy’s potential advantages for patients with Parkinson disease.

Here's what is coming soon to NeurologyLive.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed why gaps remain in screening for patients with Parkinson disease who may be eligible for device-aided therapies.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 14, 2021.

Mindy K. Bixby, DO and Laxman Bahroo, DO give key advice to community neurologists and emphasize the importance of effective communication between patients and providers.

Key opinion leaders in Parkinson’s Disease discuss the importance of improving quality of life and access to care when managing OFF episodes for patients during COVID-19.

A recent study showed improvements in animals with mutant huntingtin protein treated with AFFiRiS AG’s investigational monoclonal antibody.

Here's what is coming soon to NeurologyLive.

A recent study identified 3 novel loci that are associated with Parkinson disease progression to dementia: RIMS2, TMEM108, and WWOX.

Neurology News Network for the week ending May 8, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 7, 2021.

The director of the Center for Neurological Restoration at Cleveland Clinic spoke to how identifying care gaps in Parkinson disease patients is not a niche issue, but part of a bigger problem.

The neurologist at University of Utah discussed the potential of using teleneurology to diagnose neurological conditions.

Leaders in neurology discuss the development of infusion formulations of apomorphine and levodopa/carbidopa as well as oral agents with novel mechanisms of extended-release delivery.

Laxman Bahroo, DO and Mindy K. Bixby, DO provide insight into factors to consider for patients with challenging off time including surgical and device-assisted therapeutic options.

In preclinical data, VY-HTT01 showed a robust and durable reduction of huntingtin mRNA and protein while distributed across core areas of Huntington disease pathology.

A survey of more than 500 individuals also found that dyskinesia impacted social interactions and reported that OFF time was isolating.

Here's what is coming soon to NeurologyLive.

AbbVie recently announced a new phase 3 study (NCT04380142), called M15-736, which will measure the efficacy, safety, and tolerability of continuous subcutaneous infusion of ABBV-951.

The chief scientific officer of the Parkinson’s Foundation and adjunct associate professor in the Department of Neuroscience and Physiology at New York University School of Medicine discussed the adoption of telemedicine in Parkinson disease care.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 30, 2021.